Volunteering for a research study can make a real difference to millions of people affected with mental health problems.
The UBC Department of Psychiatry conducts multiple studies on the causes of mental disorders and on potential new treatments.
Research studies aiming to evaluate the effectiveness of potential treatments are called clinical trials. Treatments can include medication, psychological therapy, neuromodulation, or other types of therapy.
For interested individuals, the research team provides detailed information about the procedures involved to enable them to reach an informed decision about their participation.
VOLUNTEER FOR A RESEARCH STUDY OR CLINICAL TRIAL IN:
Major Depressive Disorder
Feasibility Study of Long-Term Light and Ion Therapy for Maintenance Treatment in Depression (LIMIT-D)
Project Lead: Dr. Raymond Lam, Professor of Psychiatry, Mood Disorders Centre, UBC
Funding: Canadian Institutes of Health Research (CIHR)
Years: 3
This study explores the use of two separate non-medication treatments, light therapy and ion therapy, as a substitute for antidepressant medications to prevent return of symptoms when stopping antidepressants (AKA relapse). We modified half of the treatment devices so that they are inactive (AKA placebo). You have a one in two chance (like a coin flip) of receiving an active device. You may be eligible for this study if you are 19-65 years old, have taken an antidepressant for depression for at least 3 months and no more than 12 months, are no longer depressed and want to stop medications, and are willing to use a study device for 30 minutes a day at home for 6 months. To find out more about this study or contact lam.mddresearch2@ubc.ca or see the resources below:
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D) Study
Project Lead: Dr. Raymond Lam, Professor of Psychiatry, Mood Disorders Centre, UBC
Funding: Canadian Institutes of Health Research (CIHR)
Years: 5
The purpose of this OPTIMUM-D study is to (1) test whether a specific combination of biomarkers discovered during our previous studies can help predict how someone will respond to treatment, and (2) to explore other possible biomarkers that may predict treatment response. This information may help us develop tests in the future that can guide treatment choice more effectively and more quickly. To find out more about this study or contact lam.mddresearch2@ubc.ca or see the resources below:
Study Eligibility & Participation Details
Additional information about clinical trials in Major Depressive Disorder can be found on the Mood Disorders Centre’s website.
Patient-Oriented Randomized Pragmatic Feasibility Trial with rTMS in Depression and Anxiety (PORT)
Project Lead: Dr. Fidel Vila-Rodriguez, Associate Professor of Psychiatry, UBC
Funding: Michael Smith Foundation for Health Research (MSFHR)
Years: 2020-2025
This trial compares the efficacy of two different neuromodulation treatments, intermittent theta-burst stimulation (iTBS) and low frequency repetitive transcranial magnetic stimulation (rTMS), for depression and anxiety symptoms in patients with treatment resistant depression (TRD), who are diagnosed with either major depressive disorder or bipolar disorder. Participants will be randomized to receive either iTBS or low frequency rTMS. This study also involves assessments of mood, blood smears, and cognitive assessments. For more information, please email ninet.lab@ubc.ca; call 604-822-7308; or visit https://ninet.med.ubc.ca
Left Intermittent Theta Burst Stimulation vs. Right Low Frequency Repetitive Transcranial Magnetic Stimulation Effectiveness in Depression and Suicidal Ideation: A Randomized Non-Inferiority Trial (LeRNIT)
Project Lead: Dr. Fidel Vila-Rodriguez, Associate Professor of Psychiatry, UBC
Funding: Canadian Institutes of Health Research (CIHR)
Years: 2020-2025
The purpose of this trial compares the efficacy of two non-invasive neuromodulation treatments, low frequency repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), in treating patients with Major Depressive Disorder and suicidal ideation. Participants will be randomized to receive either daily iTBS or daily rTMS over 6 weeks. The study includes assessments of mood, MRI brain scan, recording of heart rhythm (ECG), cognitive assessments. For more information, please email ninet.lab@ubc.ca; call 604-822-7308; or visit https://ninet.med.ubc.ca
Additional information about clinical trials in Interventional Brain Medicine can be found on NINET Lab’s website here…
Bipolar Disorder
Cannabidiol Adjunctive Therapy for Acute Bipolar Depression: A Randomized Double-Blind, Placebo Controlled Trial
Project Lead: Dr. Lakshmi Yatham, Professor of Psychiatry, UBC
Funding: Canadian Institute of Health Research
Years: 2023-2029
This study investigates whether adding Cannabidiol (CBD) to the current medications of people diagnosed with bipolar disorder improves symptoms of depression over a 6-week period compared to a placebo. We are seeking people diagnosed with bipolar disorder (type 1 or 2) who are 19-70 years of age, currently experiencing a depressive episode, and taking a medication for mood stabilization (lithium, valproate/epival, risperidone, olanzapine, quetiapine, aripiprazole, ziprasidone, lamotrigine or a combination of these). The study involves clinical questionnaires, blood samples, and tests of memory, attention, and concentration. Compensation will be provided for participation. For more information, please email bipolar.research@ubc.ca or call at 604-822-8045.
More information can also be found at: https://bit.ly/UBCCBD